Markel Group Inc. Acquires 1,000 Shares of Thermo Fisher Scientific Inc. $TMO

Markel Group Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 74,100 shares of the medical research company’s stock after purchasing an additional 1,000 shares during the period. Markel Group Inc.’s holdings in Thermo Fisher Scientific were worth $50,021,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Polaris Financial Partners acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $32,000. Laurel Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific in the third quarter valued at $32,000. Kilter Group LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $25,000. Legacy Wealth Managment LLC ID boosted its stake in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the last quarter. Finally, Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $26,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 76,199 shares of company stock worth $45,896,780 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TMO. Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, October 15th. They issued a “buy” rating for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. UBS Group reissued a “buy” rating and issued a $800.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, October 22nd. Finally, Barclays upped their price objective on Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $689.10.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $698.24 on Wednesday. The stock has a market capitalization of $258.71 billion, a PE ratio of 36.83, a price-to-earnings-growth ratio of 2.78 and a beta of 0.84. The business’s fifty day moving average price is $657.33 and its 200 day moving average price is $553.71. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. The firm had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.79 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.